Experienced in Thalassemia

Dr. Daniel C. Rausch

Hematology Oncology | Hematology | Oncology
Central Maine Medical Center
300 Main St, 
Lewiston, ME 
 (2349.3 mi)
Accepting New Patients
Offers Telehealth
Experienced in Thalassemia
Central Maine Medical Center
300 Main St, 
Lewiston, ME 
 (2349.3 mi)
OverviewInsuranceLocationsClinical Research

Overview

Daniel Rausch is a Hematologist Oncology specialist and a Hematologist in Lewiston, Maine. Dr. Rausch and is rated as an Experienced provider by MediFind in the treatment of Thalassemia. His top areas of expertise are Gastroesophageal Junction Cancer, Familial Colorectal Cancer, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia. Dr. Rausch is currently accepting new patients.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NH
Hospital Affiliations
Bridgton Hospital
Mainehealth Stephens Hospital
St Mary's Regional Medical Center
Central Maine Medical Center
Rumford Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Anthem
  •  Humana

Locations

CENTRAL MAINE MEDICAL CENTER
300 Main St, Lewiston, ME 04240

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Bendamustine, Rituximab
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2024
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Experienced in Thalassemia
Dr. Milaim I. Mustafa
Hematology Oncology | Hematology | Oncology
Experienced in Thalassemia
Dr. Milaim I. Mustafa
Hematology Oncology | Hematology | Oncology

Mercy Hospital

195 Fore River Pkwy, Suite 360, 
Portland, ME 
 (31.5 mi)
207-553-6868
Languages Spoken:
English, Albanian, Serbo Croatian, Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Milaim Mustafa is a Hematologist Oncology specialist and a Hematologist in Portland, Maine. Dr. Mustafa and is rated as an Advanced provider by MediFind in the treatment of Thalassemia. His top areas of expertise are Anemia, Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Gliosarcoma, and Bone Marrow Aspiration. Dr. Mustafa is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile